In December 2025, the FDA approved the first oral formulation of Wegovy (semaglutide 25 mg) for chronic weight management in obese adults[1][5][6]. It is the first GLP-1 receptor agonist tablet approved specifically for weight loss, as opposed to the once-weekly injectable version[1][2][3][5]. The approval was supported by the results of the OASIS-4 phase III clinical trial, which showed significant weight reduction and improvement in cardio-metabolic parameters compared to placebo[1]. The tablet is taken once a day on an empty stomach and is a convenient alternative to injections with the same weight loss[1][2][3]. Novo Nordisk plans to launch the pill on the US market in early January 2026[1][3]. The company also submitted applications to European regulatory authorities in the second half of 2025[1]. Treatment should be combined with diet and lifestyle[1].